Basics Gilead Sciences, Inc. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. IPO Date: January 3, 1994 Sector: Healthcare Industry: Biotech Market Cap: $150.4B Activated in VL: True Average Daily Range Avg Daily Range: $0.74 | 1.13% Avg Daily Range (30 D): $1.58 | 1.29% Avg Daily Range (90 D): $1.33 | 1.13% Institutional Daily Volume Avg Daily Volume: 7.32M Avg Daily Volume (30 D): 5.08M Avg Daily Volume (90 D): 5.09M Trade Size Avg Trade Size (Sh.): 137 Avg Trade Size (Sh.) (30 D): 56 Avg Trade Size (Sh.) (90 D): 60 Institutional Trades Total Inst.Trades: 122,143 Avg Inst. Trade: $5.32M Avg Inst. Trade (30 D): $14.75M Avg Inst. Trade (90 D): $16.07M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 21 Market Closing Trades Avg Closing Trade: $55.98M Avg Closing Trade (30 D): $147.91M Avg Closing Trade (90 D): $141.4M Avg Closing Volume: 846.78K     News Dec 6, 2025 @ 2:30 PM Nurix Therapeutics Presents New Data Demonstrating... Source: Nurix Therapeutics Dec 5, 2025 @ 10:41 AM CAR T-Cell Therapy Market Industry Trends and Glob... Source: Researchandmarkets.Com Dec 3, 2025 @ 2:34 PM Scholar Rock Stock Is Still Down 40% From 2021 Hig... Source: Jonathan Ponciano Dec 1, 2025 @ 12:00 PM Nurix Therapeutics Announces Webcast to Review New... Source: Nurix Therapeutics Nov 27, 2025 @ 4:00 PM U.S. CAR T-Cell Therapies Market Grows at 30.4% CA... Source: Towards Healthcare Financials   TTM Q3 2025 Q2 2025 Basic EPS $6.5 $2.46 $1.57 Diluted EPS $6.46 $2.43 $1.56 Revenue $ 29.09B $ 7.77B $ 7.08B Gross Profit $ 22.9B $ 6.2B $ 5.58B Net Income / Loss $ 8.11B $ 3.05B $ 1.96B Operating Income / Loss $ 10.49B $ 3.33B $ 2.47B Cost of Revenue $ 6.19B $ 1.57B $ 1.5B Net Cash Flow $ 2.29B $ 2.19B $ -2783M PE Ratio 18.77     Splits Jan 28, 2013:   2:1 Jun 25, 2007:   2:1 Sep 07, 2004:   2:1 Mar 08, 2002:   2:1 Feb 22, 2001:   2:1